Clinical Trial Update: Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating paclitaxel with or without carboplatin and/or bevacizumab, followed by doxorubicin and cyclophosphamide, in patients with breast canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Male Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7 | Phase 2 | Status: COMPLETED | Results posted: 2015-03-23